Thus, it is conceivable that the increase in intermediate (CD14++CD16+) monocytes is more actively triggered by the primary tumor, while tumor progression in metastatic disease results in a Th2-type cytokine milieu with counteracting effects. The gene discussed is CD14; the disease is neoplasm.